Cardiff Oncology (CRDF) Stock Overview
A clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CRDF Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.92 |
| 52 Week High | US$4.56 |
| 52 Week Low | US$1.48 |
| Beta | 1.37 |
| 1 Month Change | 20.00% |
| 3 Month Change | -20.33% |
| 1 Year Change | -49.34% |
| 3 Year Change | 13.61% |
| 5 Year Change | -80.93% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity
Jun 27Is Cardiff Oncology (NASDAQ:CRDF) In A Good Position To Deliver On Growth Plans?
May 21
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Feb 18Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Dec 12Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Shareholder Returns
| CRDF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | -3.0% | -1.0% |
| 1Y | -49.3% | 24.8% | 19.4% |
Return vs Industry: CRDF underperformed the US Biotechs industry which returned 22.5% over the past year.
Return vs Market: CRDF underperformed the US Market which returned 16.8% over the past year.
Price Volatility
| CRDF volatility | |
|---|---|
| CRDF Average Weekly Movement | 15.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CRDF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRDF's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 31 | Mani Mohindru | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer.
Cardiff Oncology, Inc. Fundamentals Summary
| CRDF fundamental statistics | |
|---|---|
| Market cap | US$129.89m |
| Earnings (TTM) | -US$45.88m |
| Revenue (TTM) | US$593.00k |
Is CRDF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDF income statement (TTM) | |
|---|---|
| Revenue | US$593.00k |
| Cost of Revenue | US$2.38m |
| Gross Profit | -US$1.78m |
| Other Expenses | US$44.09m |
| Earnings | -US$45.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | -300.67% |
| Net Profit Margin | -7,736.26% |
| Debt/Equity Ratio | 0% |
How did CRDF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/17 06:55 |
| End of Day Share Price | 2026/03/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardiff Oncology, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |